Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3351000
Max Phase: Preclinical
Molecular Formula: C21H29N10O18P3
Molecular Weight: 802.44
Molecule Type: Small molecule
Associated Items:
ID: ALA3351000
Max Phase: Preclinical
Molecular Formula: C21H29N10O18P3
Molecular Weight: 802.44
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[n+]1cn([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c2nc(N)nc(O)c21
Standard InChI: InChI=1S/C21H29N10O18P3/c1-29-5-31(15-9(29)17(37)28-21(23)26-15)19-13(35)11(33)7(47-19)3-45-51(40,41)49-52(42,43)48-50(38,39)44-2-6-10(32)12(34)18(46-6)30-4-24-8-14(30)25-20(22)27-16(8)36/h4-7,10-13,18-19,32-35H,2-3H2,1H3,(H8-,22,23,25,26,27,28,36,37,38,39,40,41,42,43)/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1
Standard InChI Key: FHHZHGZBHYYWTG-INFSMZHSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 802.44 | Molecular Weight (Monoisotopic): 802.0874 | AlogP: -4.77 | #Rotatable Bonds: 12 |
Polar Surface Area: 421.46 | Molecular Species: ACID | HBA: 24 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 28 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.86 | CX Basic pKa: 1.88 | CX LogP: -9.66 | CX LogD: -14.32 |
Aromatic Rings: 4 | Heavy Atoms: 52 | QED Weighted: 0.05 | Np Likeness Score: 0.70 |
1. Kowalska J, Lukaszewicz M, Zuberek J, Ziemniak M, Darzynkiewicz E, Jemielity J.. (2009) Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of cap-dependent translation., 19 (7): [PMID:19269171] [10.1016/j.bmcl.2009.02.053] |
2. Rydzik AM, Kulis M, Lukaszewicz M, Kowalska J, Zuberek J, Darzynkiewicz ZM, Darzynkiewicz E, Jemielity J.. (2012) Synthesis and properties of mRNA cap analogs containing imidodiphosphate moiety--fairly mimicking natural cap structure, yet resistant to enzymatic hydrolysis., 20 (5): [PMID:22316555] [10.1016/j.bmc.2012.01.013] |
3. Warminski M, Kowalska J, Buck J, Zuberek J, Lukaszewicz M, Nicola C, Kuhn AN, Sahin U, Darzynkiewicz E, Jemielity J.. (2013) The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation., 23 (13): [PMID:23726029] [10.1016/j.bmcl.2013.05.001] |
4. Ziemniak M, Kowalska J, Lukaszewicz M, Zuberek J, Wnek K, Darzynkiewicz E, Jemielity J.. (2015) Phosphate-modified analogues of m(7)GTP and m(7)Gppppm(7)G-Synthesis and biochemical properties., 23 (17): [PMID:26264844] [10.1016/j.bmc.2015.07.052] |
5. (2009) Inhibition of DCPS, |
Source(2):